Related Experiment Video

Updated: Jul 31, 2025

Isolation of Macrophage Subsets and Stromal Cells from Human and Mouse Myocardial Specimens
07:25

Isolation of Macrophage Subsets and Stromal Cells from Human and Mouse Myocardial Specimens

Published on: December 17, 2019

8.2K

Emerging roles of macrophages in heart failure and associated treatment approaches

Lan Xie1, Jinyong Chen1, Yidong Wang1

  • 1Department of Cardiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Therapeutic Advances in Chronic Disease
|May 8, 2023
PubMed

Insights

Inflammation drives heart failure progression. Macrophages, key immune cells, are central to cardiac injury and remodeling, presenting potential therapeutic targets for heart failure treatment.

Area of Science:

  • Cardiovascular Science
  • Immunology
  • Cell Biology

Background:

  • Heart failure remains a leading cause of global morbidity and mortality despite therapeutic advances.
  • Inflammation is a critical factor in adverse cardiac remodeling, contributing to heart failure development.
  • Macrophages are essential innate immune cells involved in all stages of cardiac injury and repair.

Purpose of the Study:

  • To review the diverse roles and phenotypes of macrophages in the heart.
  • To evaluate macrophages as potential therapeutic targets for heart failure.
  • To identify current challenges and knowledge gaps in targeting macrophages for heart failure.

Main Methods:

  • Review of in vivo and in vitro experimental findings.
  • Analysis of macrophage polarization and function in cardiac contexts.
  • Synthesis of literature on macrophage heterogeneity and therapeutic potential.

Main Results:

  • Macrophages exhibit significant phenotypic heterogeneity.
  • Macrophage polarization is regulated by the cardiac microenvironment.
  • Macrophages play governing roles in infarcted, inflamed, and aging hearts.

Conclusions:

  • Macrophages are pivotal in heart failure pathogenesis.
  • Targeting macrophage phenotypes offers a promising therapeutic strategy for heart failure.
  • Further research is needed to overcome challenges in clinical translation.

Keywords:
heart failureinflammationmacrophagemyocardial infarctionmyocarditisstem cell therapy

More Related Videos

Phenotypic Characterization of Macrophages from Rat Kidney by Flow Cytometry07:14

Phenotypic Characterization of Macrophages from Rat Kidney by Flow Cytometry

Published on: October 18, 2016

14.9K
Analyzing Ex Vivo Metabolic Flux in Splenic and Cardiac Macrophages and Bone Marrow Monocytes06:26

Analyzing Ex Vivo Metabolic Flux in Splenic and Cardiac Macrophages and Bone Marrow Monocytes

Published on: March 28, 2025

361

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
20
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.7K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
19
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
19
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
17
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
474